Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905489 | 0.74 | HRH3 (0.76) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL21096638 | 0.73 | HRH3 (0.74) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL12041349 | 0.71 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL21061867 | 0.71 | HRH3 (0.49) | HRH3KCNH2KDM4EALDH1A1GLA | |
| SCHEMBL4462960 | 0.70 | ACACB (0.50) | — | |
| SCHEMBL21061798 | 0.70 | HRH3 (0.70) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL21061868 | 0.69 | HRH3 (0.47) | HRH3KCNH2KDM4EALDH1A1GLA | |
| SCHEMBL12041256 | 0.67 | HRH3 (0.81) | HRH3KCNH2 | |
| SCHEMBL9902620 | 0.66 | GRM5 (0.45) | ALDH1A1 | |
| Benzene SCHEMBL9903610 | 0.66 | SMN1; SMN2 (0.48) | HRH3KDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | claimed |
| EP-1986701-B1 | OPTICAL AGENTS FOR USE IN SURGERY | MALLINCKRODT LLC (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | HRH3 462/4885KCNH2 647/4885KDM4E 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.